drugset / Trial / NCT00654745

18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics

NCT00654745

Phase 4 Completed 207 enrolled Daiichi Sankyo
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine if olmesartan plus amlodipine combination therapy alone and with hydrochlorothiazide will be safe and effective to reduce high blood pressure in hypertensive, type 2 diabetic subjects.

Timeline

Start
2008-05
Primary completion
2009-04
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg
Subject Amlodipine Other / unclassified 10 mg
Subject Hydrochlorothiazide Unknown 12.5 mg
Subject Hydrochlorothiazide Unknown 25 mg
Subject Olmesartan medoxomil Unknown 20 mg
Subject Olmesartan medoxomil Unknown 40 mg